Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dodick

Showing results (431-440 of 620) with videos related to

Pageof 62
Sort By:
Journal of Neurology, Neurosurgery, and Psychiatry|April 21, 2019
Onset of efficacy and duration of response of galcanezumab for the prevention of episodic migraine: a post-hoc analysisPeter J Goadsby, David W Dodick, James M Martinez, et al.
Neurology|November 17, 2022
Effect of Atogepant for Preventive Migraine Treatment on Patient-Reported Outcomes in the Randomized, Double-blind, Phase 3 ADVANCE TrialRichard B Lipton, Patricia Pozo-Rosich, Andrew M Blumenfeld, et al.
Cephalalgia : an International Journal of Headache|September 26, 2019
CGRP-dependent and independent mechanisms of acute and persistent post-traumatic headache following mild traumatic brain injury in miceEdita Navratilova, Jill Rau, Janice Oyarzo, et al.
Headache|October 21, 2018
Migraine in America Symptoms and Treatment (MAST) Study: Baseline Study Methods, Treatment Patterns, and Gender DifferencesRichard B Lipton, Sagar Munjal, Aftab Alam, et al.
The Journal of Headache and Pain|May 26, 2018
Factors associated with acute medication overuse in people with migraine: results from the 2017 migraine in America symptoms and treatment (MAST) studyTodd J Schwedt, Aftab Alam, Michael L Reed, et al.
Cephalalgia : an International Journal of Headache|November 4, 2020
Medication overuse in a subgroup analysis of phase 3 placebo-controlled studies of galcanezumab in the prevention of episodic and chronic migraineDavid W Dodick, Erin G Doty, Sheena K Aurora, et al.
Headache|May 22, 2021
Patient experience of telemedicine for headache care during the COVID-19 pandemic: An American Migraine Foundation survey studyChia-Chun Chiang, Rashmi Halker Singh, Nim Lalvani, et al.
JAMA Neurology|December 20, 2021
Assessment of Erenumab Safety and Efficacy in Patients With Migraine With and Without Aura: A Secondary Analysis of Randomized Clinical TrialsMessoud Ashina, Peter J Goadsby, David W Dodick, et al.
Headache|August 15, 2019
Unmet Acute Treatment Needs From the 2017 Migraine in America Symptoms and Treatment StudyRichard B Lipton, Sagar Munjal, Dawn C Buse, et al.
Current Medical Research and Opinion|April 7, 2005
How treatment priorities influence triptan preferences in clinical practice: perspectives of migraine sufferers, neurologists, and primary care physiciansR B Lipton, F M Cutrer, P J Goadsby, et al.
Pageof 62

Showing results (431-440 of 620) with videos related to

Sort By:
Pageof 62
Journal of Neurology, Neurosurgery, and Psychiatry|April 21, 2019
Onset of efficacy and duration of response of galcanezumab for the prevention of episodic migraine: a post-hoc analysisPeter J Goadsby, David W Dodick, James M Martinez, et al.
Neurology|November 17, 2022
Effect of Atogepant for Preventive Migraine Treatment on Patient-Reported Outcomes in the Randomized, Double-blind, Phase 3 ADVANCE TrialRichard B Lipton, Patricia Pozo-Rosich, Andrew M Blumenfeld, et al.
Cephalalgia : an International Journal of Headache|September 26, 2019
CGRP-dependent and independent mechanisms of acute and persistent post-traumatic headache following mild traumatic brain injury in miceEdita Navratilova, Jill Rau, Janice Oyarzo, et al.
Headache|October 21, 2018
Migraine in America Symptoms and Treatment (MAST) Study: Baseline Study Methods, Treatment Patterns, and Gender DifferencesRichard B Lipton, Sagar Munjal, Aftab Alam, et al.
The Journal of Headache and Pain|May 26, 2018
Factors associated with acute medication overuse in people with migraine: results from the 2017 migraine in America symptoms and treatment (MAST) studyTodd J Schwedt, Aftab Alam, Michael L Reed, et al.
Cephalalgia : an International Journal of Headache|November 4, 2020
Medication overuse in a subgroup analysis of phase 3 placebo-controlled studies of galcanezumab in the prevention of episodic and chronic migraineDavid W Dodick, Erin G Doty, Sheena K Aurora, et al.
Headache|May 22, 2021
Patient experience of telemedicine for headache care during the COVID-19 pandemic: An American Migraine Foundation survey studyChia-Chun Chiang, Rashmi Halker Singh, Nim Lalvani, et al.
JAMA Neurology|December 20, 2021
Assessment of Erenumab Safety and Efficacy in Patients With Migraine With and Without Aura: A Secondary Analysis of Randomized Clinical TrialsMessoud Ashina, Peter J Goadsby, David W Dodick, et al.
Headache|August 15, 2019
Unmet Acute Treatment Needs From the 2017 Migraine in America Symptoms and Treatment StudyRichard B Lipton, Sagar Munjal, Dawn C Buse, et al.
Current Medical Research and Opinion|April 7, 2005
How treatment priorities influence triptan preferences in clinical practice: perspectives of migraine sufferers, neurologists, and primary care physiciansR B Lipton, F M Cutrer, P J Goadsby, et al.
Pageof 62